Authors
Latest:
Bispecifics in R/R MM: Key TakeawaysPanelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices to ensure equitable access to bispecific therapies, highlighting that it’s an exciting time in myeloma treatment with patient-friendly options that can be administered closer to home, and concluding that virtually no patient should be denied exposure to bispecific therapy before discontinuing treatment, while anticipating that de-escalated Q4 weekly schedules and trispecific agents will transform current practice patterns in the coming years.
Latest:
Oncology Peer Review On-The-Go: Integrative Oncology in Young Population with Breast CancerYancey Warren, Jr, MD, MAT, and Lejla Hadzikadic-Gusic, MD, MSc, spoke with CancerNetwork® about their work investigating the use of integrative oncology services among young patients diagnosed with breast cancer.
Latest:
Advancing CML Management Towards an Ideal Patient JourneyThe panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
The Future of CAR-T: Advancing Myeloma Treatment StrategiesPanelists discuss the evolving role of chimeric antigen receptor T-cell therapy in earlier lines of treatment for multiple myeloma, with a focus on upcoming advances for patients with standard-risk disease and the impact of multidisciplinary collaboration on improving patient care and outcomes.
Latest:
The Management of Relapsed and Refractory Multiple MyelomaZhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.
Latest:
Taking a “Cross-Cutting Approach” With Cancer VaccinationsCancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.
Latest:
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaThis clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Latest:
Best Practices for the Medical Oncology BoardsA group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Latest:
Advancing Glioblastoma Research Through a Phase 3 Niraparib TrialInvestigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.
Latest:
Unmet Needs and Future Directions in the Management of Multiple MyelomaExperts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
Triplet Combination Strategies to Manage Metastatic HSPCLooking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.
Latest:
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case ReportHans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.
Latest:
ADCs May “Change the World” in Gynecologic Cancer ManagementBrian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Advancing Research and Targeting Genomic Alterations in Pancreatic CancerTanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
